Gilead Sciences, Inc. (NASDAQ:GILD) Stock Position Decreased by Moloney Securities Asset Management LLC

Moloney Securities Asset Management LLC lessened its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 89.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,531 shares of the biopharmaceutical company's stock after selling 22,629 shares during the period. Moloney Securities Asset Management LLC's holdings in Gilead Sciences were worth $284,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of GILD. Smallwood Wealth Investment Management LLC acquired a new position in shares of Gilead Sciences during the first quarter worth about $25,000. Goodman Advisory Group LLC acquired a new position in shares of Gilead Sciences during the first quarter worth about $29,000. Annis Gardner Whiting Capital Advisors LLC lifted its stake in shares of Gilead Sciences by 158.8% during the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock worth $33,000 after purchasing an additional 216 shares in the last quarter. Core Alternative Capital lifted its stake in shares of Gilead Sciences by 370.8% during the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 241 shares in the last quarter. Finally, Lee Danner & Bass Inc. acquired a new position in shares of Gilead Sciences during the fourth quarter worth about $41,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Oppenheimer cut their price target on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, April 25th. Morgan Stanley boosted their price target on Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research note on Friday, April 25th. Cantor Fitzgerald initiated coverage on Gilead Sciences in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price objective on the stock. Finally, JPMorgan Chase & Co. upped their price objective on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Nine equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $111.38.

Gilead Sciences Stock Performance

GILD stock traded down $4.90 on Friday, reaching $109.64. The company's stock had a trading volume of 6,115,020 shares, compared to its average volume of 7,692,547. Gilead Sciences, Inc. has a 52 week low of $69.91 and a 52 week high of $119.96. The company has a market capitalization of $136.38 billion, a P/E ratio of 23.08, a price-to-earnings-growth ratio of 0.74 and a beta of 0.29. The firm has a fifty day moving average of $107.74 and a two-hundred day moving average of $104.61. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The business had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. During the same period in the prior year, the company posted ($1.32) EPS. The business's revenue for the quarter was down .3% compared to the same quarter last year. As a group, analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, June 27th. Shareholders of record on Friday, June 13th were paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.88%. The ex-dividend date of this dividend was Friday, June 13th. Gilead Sciences's payout ratio is currently 66.53%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of the stock in a transaction on Friday, May 30th. The stock was sold at an average price of $110.42, for a total transaction of $1,104,200.00. Following the completion of the transaction, the chief executive officer directly owned 620,268 shares of the company's stock, valued at approximately $68,489,992.56. This trade represents a 1.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Monday, June 16th. The shares were sold at an average price of $110.17, for a total value of $275,425.00. Following the transaction, the chief financial officer directly owned 165,110 shares of the company's stock, valued at approximately $18,190,168.70. The trade was a 1.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 58,500 shares of company stock valued at $6,340,745. 0.27% of the stock is owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.